MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

about

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Item

http://www.wikidata.org/entity/Q47108370

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@en

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@nl

type

Item

label

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@en

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@nl

prefLabel

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@en

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy.

@nl

P1476

MYCN-amplified stage 2/3 neuro ...... era of anti-GD2 immunotherapy

@en

P2093

Brian H Kushner

http://www.w3.org/2001/XMLSchema#string

Ellen M Basu

http://www.w3.org/2001/XMLSchema#string

Irene Y Cheung

http://www.w3.org/2001/XMLSchema#string

Karima Yataghene

http://www.w3.org/2001/XMLSchema#string

Kim Kramer

http://www.w3.org/2001/XMLSchema#string

Michael P LaQuaglia

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

Stephen S Roberts

http://www.w3.org/2001/XMLSchema#string

Suzanne L Wolden

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Neuroblastoma: issues in transplantation

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

P304

95293-95302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20513

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shakeel Modak

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29221128

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5707022

http://www.w3.org/2001/XMLSchema#string